Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, including one-third of cases overexpressing MYC and BCL2 proteins (double expressor lymphoma, DEL) and 5-10% of patients with chromosomal rearrangements of MYC, BCL2 and/or BCL-6 (double/triple-hit lymphomas, DH/TH). TP53 mutations ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Dodero, Anna, Guidetti, Anna, Marino, Fabrizio, Tucci, Alessandra, Barretta, Francesco, Re, Alessandro, Balzarotti, Monica, Monfrini, Cristiana Carniti Chiara, Chiappella, Annalisa, Cabras, Antonello, Facchetti, Fabio, Pennisi, Martina, Rahal, Daoud, Monti, Valentina, Devizzi, Liliana, Miceli, Rosalba, Cocito, Federica, Farina, Lucia, Ricci, Francesca, Rossi, Giuseppe, Carlo-Stella, Carmelo, Corradini, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052894/
https://www.ncbi.nlm.nih.gov/pubmed/34289655
http://dx.doi.org/10.3324/haematol.2021.278638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052894/
https://www.ncbi.nlm.nih.gov/pubmed/34289655
http://dx.doi.org/10.3324/haematol.2021.278638

Ejemplares similares